International prognostic score for asymptomatic early-stage
chronic lymphocytic leukemia

J 2020

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING et. al.

Základní údaje

Originální název

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Autoři

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK (203 Česká republika, domácí), F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ (203 Česká republika, domácí), C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ (203 Česká republika, domácí), F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK a D. ROSSI (garant)

Vydání

Blood, Washington DC, USA, American Society of Hematology, 2020, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 22.113

Kód RIV

RIV/00216224:14110/20:00117894

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/blood.2019003453

UT WoS

000535968000010

Klíčová slova anglicky

chronic lymphocytic leukemia; prognostic score

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 1. 2021 14:21, Mgr. Tereza Miškechová

Anotace

V originále

Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV19-03-00091, projekt VaV

Název: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby

Investor: Ministerstvo zdravotnictví ČR, Comprehensive prognostic and predictive panel for chronic lymphocytic leukemia: a next-generation sequencing tool suitable for clinical practice and study of genetic architecture behind the disease progress

Citovat

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK a D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. Washington DC, USA: American Society of Hematology, 2020, roč. 135, č. 21, s. 1859-1869. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2019003453.

@article{1730622,
   author = {Condoluci, A. and di Bergamo, L. T. and Langerbeins, P. and Hoechstetter, M. A. and Herling, C. D. and De Paoli, L. and Delgado, J. and Rabe, K. G. and Gentile, M. and Doubek, Michael and Mauro, F. R. and Chiodin, G. and Mattsson, M. and Bahlo, J. and Cutrona, G. and Kotašková, Jana and Deambrogi, C. and Smedby, K. E. and Spina, V. and Bruscaggin, A. and Wu, W. and Moia, R. and Bianchi, E. and Gerber, B. and Zucca, E. and Gillessen, S. and Ghielmini, M. and Cavalli, F. and Stussi, G. and Hess, M. A. and Baumann, T. S. and Neri, A. and Ferrarini, M. and Rosenquist, R. and Forconi, F. and Foa, R. and Pospíšilová, Šárka and Morabito, F. and Stilgenbauer, S. and Dohner, H. and Parikh, S. A. and Wierda, W. G. and Montserrat, E. and Gaidano, G. and Hallek, M. and Rossi, D.},
   article_location = {Washington DC, USA},
   article_number = {21},
   doi = {http://dx.doi.org/10.1182/blood.2019003453},
   keywords = {chronic lymphocytic leukemia; prognostic score},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia},
   url = {https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo},
   volume = {135},
   year = {2020}
}

TY  - JOUR
ID  - 1730622
AU  - Condoluci, A. - di Bergamo, L. T. - Langerbeins, P. - Hoechstetter, M. A. - Herling, C. D. - De Paoli, L. - Delgado, J. - Rabe, K. G. - Gentile, M. - Doubek, Michael - Mauro, F. R. - Chiodin, G. - Mattsson, M. - Bahlo, J. - Cutrona, G. - Kotašková, Jana - Deambrogi, C. - Smedby, K. E. - Spina, V. - Bruscaggin, A. - Wu, W. - Moia, R. - Bianchi, E. - Gerber, B. - Zucca, E. - Gillessen, S. - Ghielmini, M. - Cavalli, F. - Stussi, G. - Hess, M. A. - Baumann, T. S. - Neri, A. - Ferrarini, M. - Rosenquist, R. - Forconi, F. - Foa, R. - Pospíšilová, Šárka - Morabito, F. - Stilgenbauer, S. - Dohner, H. - Parikh, S. A. - Wierda, W. G. - Montserrat, E. - Gaidano, G. - Hallek, M. - Rossi, D.
PY  - 2020
TI  - International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
JF  - Blood
VL  - 135
IS  - 21
SP  - 1859-1869
EP  - 1859-1869
PB  - American Society of Hematology
SN  - 00064971
KW  - chronic lymphocytic leukemia
KW  - prognostic score
UR  - https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo
L2  - https://watermark.silverchair.com/bloodbld2019003453.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-wwggPoBgkqhkiG9w0BBwagggPZMIID1QIBADCCA84GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMXRXeaAY25mjozM5SAgEQgIIDnxhMmZAU5cNiFCUDj79Os54hBBpUZ00qooo
N2  - Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.
ER  -

CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK a D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2020, roč.~135, č.~21, s.~1859-1869. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2019003453.

Podrobný výpis o publikaci